Literature DB >> 18457835

Toxoplasma gondii: serological characterization and immunogenicity of recombinant surface antigen 2 (SAG2) expressed in the yeast Pichia pastoris.

Yee Ling Lau1, Mun Yik Fong.   

Abstract

The full length surface antigen 2 (SAG2) gene of the protozoan parasite Toxoplasma gondii was cloned and intracellularly expressed in the Pichia pastoris expression system. The molecular weight of the expressed recombinant SAG2 (36 kDa) was much larger than the native SAG2 (22 kDa). This discrepancy in size was due to hyperglycosylation, as deglycosylation assay reduced the size of the recombinant SAG2 to 22 kDa. Despite being hyperglycosylated, the recombinant SAG2 reacted strongly with pooled anti-Toxoplasma human serum, pooled anti-Toxoplasma mouse serum and a SAG2-specific monoclonal antibody. The glycosylated recombinant SAG2 was further evaluated in Western blot and in-house enzyme-linked immunosorbent assay (ELISA) using 80 human serum samples, including confirmed early acute (IgM positive, IgG negative; n=20), acute (IgM positive, IgG positive; n=20) and chronic (IgM negative, IgG positive; n=20) toxoplasmosis patients, and toxoplasmosis negative control patients (n=20). Results of the Western blot showed that the recombinant SAG2 reacted with all 60 samples of the toxoplasmosis cases but not with the Toxoplasma-negative samples. The sensitivity of in-house ELISA was 80%, 95% and 100% for early acute, acute and chronic patients' serum samples, respectively. Vaccination study showed that serum from mice immunised with the glycosylated recombinant SAG2 reacted specifically with the native SAG2 of T. gondii. The mice were significantly protected against lethal challenge with live T. gondii RH strain tachyzoites (P<0.01) and their survival time was increased compared to controls. Therefore, the present study shows that the P. pastoris-derived recombinant SAG2 was specific and suitable for use as antigen for detecting anti-Toxoplasma IgG and IgM antibodies. The vaccination study showed that recombinant SAG2 protein was immunoprotective in mice against lethal challenge.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18457835     DOI: 10.1016/j.exppara.2008.03.016

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  18 in total

1.  Structural and functional characterization of SporoSAG: a SAG2-related surface antigen from Toxoplasma gondii.

Authors:  Joanna Crawford; Erika Lamb; James Wasmuth; Ognjen Grujic; Michael E Grigg; Martin J Boulanger
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

2.  Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis.

Authors:  M M Liu; Z G Yuan; G H Peng; D H Zhou; X H He; C Yan; C C Yin; Y He; R Q Lin; H Q Song; X Q Zhu
Journal:  Parasitol Res       Date:  2010-02-23       Impact factor: 2.289

3.  Detection of antibodies to Toxoplasma gondii in domesticated ruminants by recombinant truncated SAG2 enzyme-linked immunosorbent assay.

Authors:  Harkirat Singh; Anup Kumar Tewari; Ashok Kumar Mishra; Biswaranjan Maharana; Vikrant Sudan; Opinder Krishan Raina; Jammi Raghavendra Rao
Journal:  Trop Anim Health Prod       Date:  2014-10-16       Impact factor: 1.559

4.  Evaluation of a recombinant multiepitope peptide for serodiagnosis of Toxoplasma gondii infection.

Authors:  Jianfang Dai; Min Jiang; Yanyun Wang; Lili Qu; Rujun Gong; Jin Si
Journal:  Clin Vaccine Immunol       Date:  2012-01-04

5.  A new MIC1-MAG1 recombinant chimeric antigen can be used instead of the Toxoplasma gondii lysate antigen in serodiagnosis of human toxoplasmosis.

Authors:  Lucyna Holec-Gąsior; Bartłomiej Ferra; Dorota Drapała; Dariusz Lautenbach; Józef Kur
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

Review 6.  Production of recombinant proteins from protozoan parasites.

Authors:  José A Fernández-Robledo; Gerardo R Vasta
Journal:  Trends Parasitol       Date:  2010-02-26

7.  Immunogenic characterization of the chimeric surface antigen 1 and 2 (SAG1/2) of Toxoplasma gondii expressed in the yeast Pichia pastoris.

Authors:  Yee Ling Lau; Girija Thiruvengadam; Wei Wei Lee; Mun Yik Fong
Journal:  Parasitol Res       Date:  2011-04-01       Impact factor: 2.289

Review 8.  Toxoplasma gondii recombinant antigens as tools for serodiagnosis of human toxoplasmosis: current status of studies.

Authors:  Lucyna Holec-Gasior
Journal:  Clin Vaccine Immunol       Date:  2013-06-19

9.  A new Toxoplasma gondii chimeric antigen containing fragments of SAG2, GRA1, and ROP1 proteins-impact of immunodominant sequences size on its diagnostic usefulness.

Authors:  Bartłomiej Ferra; Lucyna Holec-Gąsior; Józef Kur
Journal:  Parasitol Res       Date:  2015-06-09       Impact factor: 2.289

10.  Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis.

Authors:  Hai-Long Wang; Ya-Qing Li; Li-Tian Yin; Xiao-Li Meng; Min Guo; Jian-Hong Zhang; Hong-Li Liu; Juan-Juan Liu; Guo-Rong Yin
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.